Nasdaq · Healthcare
Adagene Inc. (ADAG)
As-reported financials and recent SEC filings for Adagene Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$7.7M
Net income
$-17.6M
Net margin
—
Diluted EPS
$-0.30
ROE
-49.8%
P/E (TTM)
—
Market cap
—
Debt / equity
0.0×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $7.7M | $103,204 | $18.1M | $9.3M | $10.2M |
| Gross profit | — | — | — | — | — |
| Operating income | $-21.4M | $-36.0M | $-23.7M | $-83.9M | $-72.4M |
| Net income | $-17.6M | $-33.4M | $-18.9M | $-80.0M | $-73.2M |
| Diluted EPS | $-0.30 | $-0.59 | $-0.35 | $-1.48 | $-1.46 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
6-K2026-07-06
View on EDGAR →SCHEDULE 13D/A2026-06-08
View on EDGAR →SCHEDULE 13G/A2026-05-15
View on EDGAR →SCHEDULE 13G2026-05-07
View on EDGAR →6-K2026-04-17
View on EDGAR →424B52026-04-02
View on EDGAR →6-K2026-04-02
View on EDGAR →424B52026-04-02
View on EDGAR →Largest Healthcare peers
Go deeper on ADAG
Search Adagene Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.